These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16316710)

  • 1. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens.
    Mesa C; de León J; Fernández LE
    Vaccine; 2006 Mar; 24(14):2692-9. PubMed ID: 16316710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors.
    Torréns I; Mendoza O; Batte A; Reyes O; Fernández LE; Mesa C; Guillén G
    Vaccine; 2005 Dec; 23(50):5768-74. PubMed ID: 16112257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions.
    Oliver L; Fernández A; Raymond J; López-Requena A; Fernández LE; Mesa C
    Vaccine; 2012 Apr; 30(19):2963-72. PubMed ID: 22391399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
    Venier C; Guthmann MD; Fernández LE; Fainboim L
    Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation.
    Mesa C; De León J; Rigley K; Fernández LE
    Vaccine; 2004 Aug; 22(23-24):3045-52. PubMed ID: 15297054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
    Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
    J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation.
    Mesa C; de León J; Rigley K; Fernández LE
    Vaccine; 2006 Apr; 24 Suppl 2():S2-42-3. PubMed ID: 16823920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New vaccines require potent adjuvants like AFPL1 and AFCo1.
    Pérez O; Lastre M; Cabrera O; del Campo J; Bracho G; Cuello M; Balboa J; Acevedo R; Zayas C; Gil D; Mora N; González D; Pérez R; González E; Barberá R; Fajardo EM; Sierra G; Solís RL; Campa C
    Scand J Immunol; 2007; 66(2-3):271-7. PubMed ID: 17635804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
    Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
    Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
    Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C
    Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programming of CTL with heat-killed Brucella abortus and antigen allows soluble antigen alone to generate effective secondary CTL.
    Inoue S; Golding B; Scott D
    Vaccine; 2005 Feb; 23(14):1730-8. PubMed ID: 15705479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
    Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; van der Burg SH; Offringa R
    Eur J Immunol; 2008 Apr; 38(4):1033-42. PubMed ID: 18350546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).
    Estevez F; Carr A; Solorzano L; Valiente O; Mesa C; Barroso O; Sierra GV; Fernandez LE
    Vaccine; 1999 Aug; 18(1-2):190-7. PubMed ID: 10501249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune adjuvant effect of TB.HSP70 to its accompanying cytotoxic T lymphocytes epitope elicits HBV specific immune response].
    Peng ML; Chen M; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jun; 14(6):406-9. PubMed ID: 16792861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
    Chaitra MG; Nayak R; Shaila MS
    Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.